MY8700597A - Acetal stabilized prostaglandin compositions - Google Patents

Acetal stabilized prostaglandin compositions

Info

Publication number
MY8700597A
MY8700597A MY597/87A MY8700597A MY8700597A MY 8700597 A MY8700597 A MY 8700597A MY 597/87 A MY597/87 A MY 597/87A MY 8700597 A MY8700597 A MY 8700597A MY 8700597 A MY8700597 A MY 8700597A
Authority
MY
Malaysia
Prior art keywords
acetal
prostaglandin compositions
stabilized prostaglandin
stabilized
compositions
Prior art date
Application number
MY597/87A
Other languages
English (en)
Inventor
Yu Cheng Der
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of MY8700597A publication Critical patent/MY8700597A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MY597/87A 1981-04-16 1987-12-30 Acetal stabilized prostaglandin compositions MY8700597A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/254,824 US4358603A (en) 1981-04-16 1981-04-16 Acetal stabilized prostaglandin compositions

Publications (1)

Publication Number Publication Date
MY8700597A true MY8700597A (en) 1987-12-31

Family

ID=22965721

Family Applications (1)

Application Number Title Priority Date Filing Date
MY597/87A MY8700597A (en) 1981-04-16 1987-12-30 Acetal stabilized prostaglandin compositions

Country Status (12)

Country Link
US (1) US4358603A (de)
EP (1) EP0063367B1 (de)
JP (1) JPS57181054A (de)
AT (1) ATE9061T1 (de)
AU (1) AU553104B2 (de)
CA (1) CA1168155A (de)
DE (1) DE3260600D1 (de)
HK (1) HK43987A (de)
IE (1) IE52854B1 (de)
MY (1) MY8700597A (de)
NZ (1) NZ200309A (de)
ZA (1) ZA822578B (de)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0668076B1 (de) * 1992-08-26 2002-09-04 Sucampo AG Stabilisierung von Prostansäurederivaten
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
AP9901643A0 (en) 1997-04-28 1999-10-02 Texas Biotechnology Corp Sulfonamides for treatment of endothelin-mediated disorders.
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US7169410B1 (en) * 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
CA2463724A1 (en) * 2001-10-16 2003-04-24 Structural Bioinformatics Inc. Organosulfur inhibitors of tyrosine phosphatases
AUPR868201A0 (en) * 2001-11-05 2001-11-29 Thorlock International Limited Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002367060A1 (en) * 2001-12-21 2003-07-30 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
ES2361403T3 (es) 2002-03-07 2011-06-16 X-Ceptor Therapeutics, Inc. Moduladores de quinazolinona de receptores nucleares.
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
EP1517684B1 (de) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
ES2532399T3 (es) 2003-03-05 2015-03-26 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP4847868B2 (ja) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
US7652044B2 (en) * 2003-06-03 2010-01-26 Novartis A.G. P-38 inhibitors
EP1911754B1 (de) 2003-08-13 2013-10-09 Takeda Pharmaceutical Company Limited Dipeptidyl-Peptidase-Hemmer
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050203184A1 (en) 2003-09-10 2005-09-15 Petasis Nicos A. Benzo lipoxin analogues
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
KR20070032700A (ko) 2004-05-20 2007-03-22 폴드알엑스 파마슈티칼스, 인크. 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, 2-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법
EP1765332A2 (de) * 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Trisubstituierte stickstoffmodulatoren von tyrosin-phosphatasen
WO2006017124A2 (en) * 2004-07-09 2006-02-16 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
EP1773348A4 (de) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc Tetrapeptid-analoga
EP1841749A1 (de) * 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Thiazol- und thiadiazolderivate als inhibitoren von tyrosinphosphatasen
EP1802303B1 (de) 2004-09-17 2011-11-02 Whitehead Institute For Biomedical Research Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
EP1866319B1 (de) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl-nukleoside und analoga
CA2598216C (en) * 2005-06-17 2014-04-08 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
JP5265369B2 (ja) * 2006-01-24 2013-08-14 株式会社アールテック・ウエノ 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法
CA2647543A1 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
AU2007313961A1 (en) 2006-10-09 2008-05-08 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2223925A1 (de) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
EP2089359A2 (de) 2006-10-31 2009-08-19 Takeda Pharmaceutical Company Limited Inhibitoren von mapk-erk-kinase
WO2009042711A1 (en) 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
JP2011504485A (ja) * 2007-11-21 2011-02-10 ファーマクシス リミテッド Ssao/vap−1のハロアリルアミン阻害剤およびその用途
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(sarm) 및 이의 용도
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
CN102300989B (zh) 2009-01-06 2015-12-09 柯尔朗恩有限责任公司 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
KR20170005191A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
WO2010111626A2 (en) 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
EP2459561A1 (de) 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly(adp-ribose)-polymerase (parp)-hemmer
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
IN2012DN04858A (de) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
JP6069661B2 (ja) 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
MX2013015373A (es) 2011-06-23 2014-02-11 Map Pharmaceuticals Inc Nuevos analogos de fluoroergolina.
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
SG11201403434YA (en) 2011-12-19 2014-09-26 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
CA2859175A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
WO2013134047A2 (en) 2012-03-07 2013-09-12 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
EP3438087A1 (de) 2012-05-02 2019-02-06 Boehringer Ingelheim International GmbH Substituierte 3-haloallylamininhibitoren von ssao und verwendungen davon
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP3406598B1 (de) 2012-06-14 2020-01-29 Mayo Foundation for Medical Education and Research Pyrazolderivate als hemmer von stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US8551535B1 (en) 2012-08-06 2013-10-08 Sarah McCann Homeopathic remedies and methods for enhancing weight loss
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
BR112015014964A2 (pt) 2012-12-21 2017-07-11 Map Pharmaceuticals Inc novos derivados de metisergida
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
CA2902232C (en) 2013-02-22 2020-12-29 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
EP2968296B1 (de) 2013-03-12 2020-09-02 The Regents of the University of California Gammasekretasemodulatoren
KR102230461B1 (ko) 2013-03-15 2021-03-22 유니버시티 오브 써던 캘리포니아 엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들
SG11201509982UA (de) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
US10472346B2 (en) 2014-10-31 2019-11-12 The General Hospital Corporation Potent gamma-secretase modulators
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
JP2018502889A (ja) 2015-01-20 2018-02-01 エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc イソエルゴリン化合物およびその使用
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc エルゴリン化合物およびその使用
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
WO2016176617A2 (en) 2015-04-29 2016-11-03 New York University Method for treating high-grade gliomas
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
JP7011596B2 (ja) 2015-12-02 2022-02-10 アストライア セラピューティクス, エルエルシー ピペリジニルノシセプチン受容体化合物
JP6849197B2 (ja) 2016-02-12 2021-03-24 ファーマクシス リミテッド リジルオキシダーゼのインドールおよびアザインドールハロアリルアミン誘導体阻害剤およびその使用
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10407437B2 (en) 2016-03-08 2019-09-10 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
EP3426301A4 (de) 2016-03-08 2019-11-06 Los Gatos Pharmaceuticals, Inc. Verbundnanopartikel und verwendungen davon
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
ES2939373T3 (es) 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
KR102874295B1 (ko) 2017-02-17 2025-10-20 에이도스 테라퓨틱스, 인코포레이티드 Ag-10, 이의 중간체, 및 이의 염을 제조하는 방법
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
EP3630758A1 (de) 2017-06-01 2020-04-08 Xoc Pharmaceuticals, Inc Ergolinderivate zur verwendung in der medizin
AU2018324070B2 (en) 2017-09-01 2023-05-18 East Carolina University Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
US20190216751A1 (en) 2017-11-15 2019-07-18 California State University Northridge Compositions and Methods for the Treatment and Prevention of Cancer
US11058668B2 (en) 2018-03-23 2021-07-13 Eidos Therapeutics, Inc. Methods of treating TTR amyloidosis using AG10
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
CN112533897B (zh) 2018-08-03 2023-07-14 法玛西斯有限公司 赖氨酰氧化酶的卤代烯丙胺砜衍生抑制剂及其用途
IL325404A (en) 2018-08-17 2026-02-01 Eidos Therapeutics Inc Spice formulations containing 3-(3-(5,3-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
EP3959292B1 (de) 2019-05-20 2025-07-02 NIRvana Sciences Inc. Farbstoffe mit geringer emission, zusammensetzungen damit und verfahren zu ihrer herstellung und verwendung
US20220249707A1 (en) 2019-05-20 2022-08-11 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
IL291345B2 (en) 2019-09-16 2024-04-01 Dice Alpha Inc Il-17a modulators and uses thereof
JP7828905B2 (ja) 2020-06-30 2026-03-12 プロセッタ バイオサイエンシズ, インク. イソキノリン誘導体、合成の方法及びそれらの使用
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CR20230472A (es) 2021-03-10 2024-03-21 Dice Molecules Sv Inc Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
US12017997B2 (en) 2021-10-22 2024-06-25 Prosetta Biosciences, Inc. Host-targeted pan-respiratory antiviral small molecule therapeutics
EP4433040A4 (de) 2022-01-03 2025-11-12 Lilac Therapeutics Inc Acyclische thiol-prodrugs
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
JP2025507621A (ja) 2022-03-02 2025-03-21 ミトパワー, インク. ニコチン酸及びリボースから誘導体化した新規プロドラッグ
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749800A (en) * 1971-11-01 1973-07-31 Upjohn Co Stable composition for dispensing pge2
US3833612A (en) * 1971-11-24 1974-09-03 Merck & Co Inc Derivatives of 5-oxo-1 beta-cyclopentane-heptanoic acid,5-ethylene acetals
US4178457A (en) * 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
US4178454A (en) * 1978-10-11 1979-12-11 Toray Industries, Inc. Stabilized prostaglandin E composition

Also Published As

Publication number Publication date
CA1168155A (en) 1984-05-29
ZA822578B (en) 1983-11-30
ATE9061T1 (de) 1984-09-15
HK43987A (en) 1987-06-12
DE3260600D1 (en) 1984-09-27
JPS57181054A (en) 1982-11-08
AU553104B2 (en) 1986-07-03
US4358603A (en) 1982-11-09
IE52854B1 (en) 1988-03-30
AU8263582A (en) 1982-10-21
NZ200309A (en) 1985-03-20
JPH0219805B2 (de) 1990-05-07
IE820889L (en) 1982-10-16
EP0063367B1 (de) 1984-08-22
EP0063367A1 (de) 1982-10-27

Similar Documents

Publication Publication Date Title
DE3260600D1 (en) Acetal stabilized prostaglandin compositions
KR840000236A (ko) 포유류의 국부용 제형의 수분 손실량을 극소화시키는 방법
ES524657A0 (es) Un procedimiento para la preparacion de una composicion profilactica de gel de fluoruro.
AU6746087A (en) Dialdehyde containing compositions
AU553873B2 (en) Improving the filling capacity of tobacco
GR74616B (de)
ES2036831T3 (es) Cabeza de distribucion para un aditivo, destinada a estar montada en un recipiente, y recipiente equipado con dicha cabeza de distribucion.
ES8800598A1 (es) Un procedimiento para preparar una composicion farmaceutica que comprende azapropanona
ZA952805B (en) Stable aqueous folinate solution
SE8007569L (sv) Fosningsmedel jemte sett att dermed framstella stabila losningar lempliga for parenteral administration
JPS53107486A (en) Stabilized nadh aqueous solution
JPS5639013A (en) Ophthalmic solution for regulating intraocular tension
GB1554048A (en) Prostacyclin derivatives
GB1272829A (en) Nickel alkoxide compound
HK26877A (en) An ether of 1-(2-hydroxyethyl)-3-methyl-pyrazolin-5-one processes for its preparation and its use as an antithrombotic agent
IT8247756A0 (it) Procedimento per la produzione disoluzioni acquose di metioninato sodico a basso contenuto di carbonato sodico
BG32858A3 (bg) Метод за получаване на кристален натриев цефамандолметанолат
MY100078A (en) Improvements relating to the expansion of tobacco.
ES484321A1 (es) Un procedimiento para la preparacion de un compuesto de 3- carbamoiloximetil-cefalosporina
AU509474B2 (en) Alcohol analogues of prostaglandins
ES395036A2 (es) Procedimiento para producir un compuesto opticamente acti- vo.
JPS5229185A (en) Semiconductor laser
JPS539312A (en) Preparation of light-stable mecobalamin or cobamamide parenteral injections
JPS57167976A (en) 2-phenylbenzotriazole-n-oxides and their preparations
IT1169037B (it) Derivati della prostaciclina, loro preparazione e impiego